Seattle Genetics (SGEN)

71.48 +2.91 (4.24%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (4/26/19 *Est.)
- M&A (3/31/18 *Est)

Latest Headlines

Form SC 13G/A SEATTLE GENETICS INC Filed by: PRICE T ROWE ASSOCIATES INC /MD/ February 14, 2019 1:59 PM - SEC Filing Form SC 13G/A SEATTLE GENETICS INC Filed by: Capital International Investors February 14, 2019 6:44 AM - SEC Filing Form SC 13G/A SEATTLE GENETICS INC Filed by: VANGUARD GROUP INC February 13, 2019 10:29 AM - SEC Filing Form 4 SEATTLE GENETICS INC For: Feb 08 Filed by: SIEGALL CLAY B February 12, 2019 6:26 PM - SEC Filing Form SC 13G SEATTLE GENETICS INC Filed by: WELLINGTON MANAGEMENT GROUP LLP February 12, 2019 10:05 AM - SEC Filing Seattle Genetics (SGEN) chieves $30 Million Milestone Payment for EC Approval of ADCETRIS in Frontline Hodgkin Lymphoma February 11, 2019 8:01 AM - StreetInsider Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma February 11, 2019 8:00 AM - BizWire Form SC 13G/A SEATTLE GENETICS INC Filed by: PRIMECAP MANAGEMENT CO/CA/ February 8, 2019 3:55 PM - SEC Filing Seattle Genetics (SGEN) PT Raised to $81 at Needham & Company February 8, 2019 1:50 PM - StreetInsider Increasing unusual option volume: AVLR SGEN COTY February 8, 2019 9:40 AM - StreetInsider Pre-Open Stock Movers 02/08: (COTY) (SKX) (MAT) Higher; (VCRA) (SGEN) (ANGI) Lower (more...) February 8, 2019 9:19 AM - StreetInsider Seattle Genetics (SGEN) PT Lowered to $64 at Piper Jaffray February 8, 2019 8:52 AM - StreetInsider Form SC 13G SEATTLE GENETICS INC Filed by: BlackRock Inc. February 8, 2019 6:10 AM - SEC Filing After-Hours Movers 02/07: (EGAN) (SKX) (MAT) Higher; (VCRA) (SGEN) (ANGI) (more...) February 7, 2019 5:26 PM - StreetInsider Form 10-K SEATTLE GENETICS INC For: Dec 31 February 7, 2019 5:13 PM - SEC Filing Form 8-K SEATTLE GENETICS INC For: Feb 07 February 7, 2019 4:08 PM - SEC Filing Seattle Genetics (SGEN) Misses Q4 EPS by 32c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus February 7, 2019 4:05 PM - StreetInsider Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results February 7, 2019 4:02 PM - BizWire Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day February 6, 2019 8:00 AM - BizWire Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019 January 22, 2019 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Jan 08 Filed by: GRYSKA DAVID W January 10, 2019 9:10 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Jan 08 Filed by: SIEGALL CLAY B January 10, 2019 8:28 PM - SEC Filing Seattle Genetics (SGEN) Reports Publication of North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma January 9, 2019 8:03 AM - StreetInsider Seattle Genetics Announces Publication of North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma January 9, 2019 8:00 AM - BizWire Seattle Genetics to Present at the J.P. Morgan Healthcare Conference December 19, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Dec 10 Filed by: SIEGALL CLAY B December 12, 2018 7:32 PM - SEC Filing Form SC 13G/A SEATTLE GENETICS INC Filed by: BAILLIE GIFFORD & CO December 6, 2018 7:21 AM - SEC Filing Form 4 SEATTLE GENETICS INC For: Nov 30 Filed by: HIMES VAUGHN B December 4, 2018 7:38 PM - SEC Filing Seattle Genetics (SGEN), Takeda Report Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin) December 4, 2018 5:51 AM - StreetInsider Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas December 3, 2018 9:15 PM - BizWire Seattle Genetics (SGEN) Provides Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma December 3, 2018 6:13 AM - StreetInsider Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting December 2, 2018 12:00 PM - BizWire Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting December 1, 2018 12:00 PM - BizWire Form 4 SEATTLE GENETICS INC For: Nov 29 Filed by: Cline Darren S November 30, 2018 6:33 PM - SEC Filing Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting November 26, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Nov 21 Filed by: Cline Darren S November 21, 2018 6:43 PM - SEC Filing Full Article List